Baker Bros. Advisors’s Vincerx Pharma, Inc. Common Stock VINC Stock Holding History

Baker Bros. Advisors’s Portfolio VINC Stock Details VINC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-11,279	Closed	-$293K	–	111
2023 Q2	$293K	Sell	11,279 -790	-7%	-$22.6K	﹤0.01%	106
2023 Q1	$251K	Hold	12,069	–	–	﹤0.01%	103
2022 Q4	$246K	Hold	12,069	–	–	﹤0.01%	110
2022 Q3	$333K	Hold	12,069	–	–	﹤0.01%	111
2022 Q2	$319K	Hold	12,069	–	–	﹤0.01%	112
2022 Q1	$966K	Hold	12,069	–	–	0.01%	110
2021 Q4	$2.46M	Hold	12,069	–	–	0.01%	103
2021 Q3	$3.9M	Buy	+12,069	New	+$3.52M	0.02%	103

Other funds holding VINC

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

SRC

Sage Rhino Capital Menlo Park, California $617M AUM 28.74% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ECM

ExodusPoint Capital Management New York $12.6B AUM 30.13% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Baker Bros. Advisors's VINC Position: Q3 2023 in Review

Baker Bros. Advisors sold out of Vincerx Pharma, Inc. Common Stock (VINC) in Q3 2023, closing a stake of 11,279 shares — an estimated $293K sold.

Baker Bros. Advisors first reported a position in VINC in Q3 2021 and held it in 8 quarters. The position peaked at $3.9M in Q3 2021. 34 funds tracked by Wall St. Rank hold VINC as of Q3 2023.

Baker Bros. Advisors reported no remaining Vincerx Pharma, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Baker Bros. Advisors sold 11,279 Vincerx Pharma, Inc. Common Stock shares in Q3 2023, an estimated $293K.
Baker Bros. Advisors first reported a position in Vincerx Pharma, Inc. Common Stock in Q3 2021 and held it in 8 quarters.
Baker Bros. Advisors's Vincerx Pharma, Inc. Common Stock position peaked at $3.9M in Q3 2021.
34 funds tracked by Wall St. Rank held Vincerx Pharma, Inc. Common Stock as of Q3 2023.

Based on Baker Bros. Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.